Bacterial partnering terms and agreements

377 views
308 views

Published on

The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors bacterial technology.

Published in: Technology, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
377
On SlideShare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Bacterial partnering terms and agreements

  1. 1. Bacterial Partnering Terms and AgreementsThe Bacterial Partnering Terms and Agreements report provides comprehensive understanding andunprecedented access to the bacterial partnering deals and agreements entered into by the worldsleading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter bacterialpartnering deals. The majority of deals are discovery or development stage whereby the licensee obtainsa right or an option right to license the licensors bacterial technology. These deals tend to bemulticomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight intothe negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilstmany smaller companies will be seeking details of the payments clauses, the devil is in the detail in termsof how payments are triggered – contract documents provide this insight where press releases do not.This report contains over 1,000 links to online copies of actual bacterial deals and contract documents assubmitted to the Securities Exchange Commission by companies and their partners. Contract documentsprovide the answers to numerous questions about a prospective partner’s flexibility on a wide range ofimportant issues, many of which will have a significant impact on each party’s ability to derive value fromthe deal.The initial chapters of this report provide an orientation of bacterial dealmaking and business activities.Chapter 1 provides an introduction to the report.Chapter 2 provides an overview of the trends in bacterial dealmaking since 2007 covering trends by year,deal type, stage of development, technology type and therapeutic indication. In addition the chapterincludes an analysis of financial deal terms by stage at signing covering headline value, upfront payment,milestone payments and royalty rates. Analysis includes median values and distribution of values for eachstage of development.Chapter 3 provides a review of the leading bacterial deals since 2007. Deals are listed by headline value,signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where thedeal has an agreement contract published at the SEC a link provides online access to the contract.Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summaryfollowed by a comprehensive listing of bacterial deals, as well as contract documents available in thepublic domain. Where available, each deal title links via Weblink to an online version of the actualcontract document, providing easy access to each contract document on demand.Chapter 5 provides comprehensive access to all bacterial deals since 2007 where a deal contract isavailable, providing the user with direct access to contracts as filed with the SEC regulatory authorities.Each deal title links via Weblink to an online version of the deal record contract document, providing easyaccess to each contract document on demand.
  2. 2. Chapter 6 provides a comprehensive directory of all bacterial partnering deals signed and announcedsince 2007. The chapter is organized by specific infectives therapy focus. Each deal title links via Weblinkto an online version of the deal record and where available, the contract document, providing easy accessto each contract document on demand.In addition, a comprehensive appendix is provided with each report of all bacterial partnering deals signedand announced since 2007. The appendices are organized by company A-Z, stage of development atsigning, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal titlelinks via Weblink to an online version of the deal record and where available, the contract document,providing easy access to each contract document on demand.The report also includes numerous tables and figures that illustrate the trends and activities in bacterialpartnering and dealmaking since 2007.In conclusion, this report provides everything a prospective dealmaker needs to know about partnering inthe research, development and commercialization of bacterial technologies and products.Buy your copy of this report @ http://www.reportsnreports.com/reports/175339-bacterial-partnering-terms-and-agreements.htmlMajor points covered in Table of Contents of this report include:Executive SummaryChapter 1 – IntroductionChapter 2 – Trends in bacterial dealmakingChapter 3 – Leading bacterial dealsChapter 4 – Bigpharma bacterial dealsChapter 5 – Bacterial partnering contracts directoryChapter 6 – Bacterial dealmaking by indicationChapter 7 – Partnering resource centerTable of Figures
  3. 3. Browse reports related to Boitechnology @http://www.reportsnreports.com/market-research/biotechnology/Report Details:Published: July 2012No. of Pages: 801Price: Single User License – US$1995 Corporate User License – US$2995Contact:Priyank TiwariTX, Dallas North - Dominion Plaza,17304, Preston Road,Suite 800, Dallas 75252Tel: +1-888-391-5441sales@reportsandreports.comConnect With Us:

×